Short Interest in Daré Bioscience, Inc. (NASDAQ:DARE) Rises By 22.2%

Daré Bioscience, Inc. (NASDAQ:DARE) was the target of a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 87,400 shares, an increase of 22.2% from the February 28th total of 71,500 shares. Currently, 1.0% of the company’s shares are sold short. Based on an average daily volume of 28,600 shares, the days-to-cover ratio is presently 3.1 days.

Daré Bioscience Stock Performance

Shares of NASDAQ:DARE traded up $0.04 during trading on Wednesday, hitting $2.94. The company’s stock had a trading volume of 2,127 shares, compared to its average volume of 45,412. Daré Bioscience has a fifty-two week low of $2.67 and a fifty-two week high of $7.56. The business has a 50 day moving average price of $3.05 and a two-hundred day moving average price of $3.28. The company has a market capitalization of $25.53 million, a PE ratio of -4.97 and a beta of 1.38.

Daré Bioscience (NASDAQ:DARE) last announced its earnings results on Monday, March 31st. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.02. The firm had revenue of ($0.06) million during the quarter, compared to analyst estimates of $1.00 million. As a group, equities analysts expect that Daré Bioscience will post -0.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Daré Bioscience in a research note on Tuesday.

Hedge Funds Weigh In On Daré Bioscience

Hedge funds have recently modified their holdings of the business. AMH Equity Ltd boosted its stake in Daré Bioscience by 50.0% during the 4th quarter. AMH Equity Ltd now owns 150,000 shares of the biotechnology company’s stock worth $468,000 after purchasing an additional 50,000 shares during the period. Geode Capital Management LLC raised its holdings in shares of Daré Bioscience by 4.0% in the fourth quarter. Geode Capital Management LLC now owns 92,653 shares of the biotechnology company’s stock valued at $289,000 after buying an additional 3,593 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Daré Bioscience by 6.7% in the fourth quarter. Renaissance Technologies LLC now owns 68,695 shares of the biotechnology company’s stock valued at $214,000 after buying an additional 4,300 shares during the last quarter. Finally, Jane Street Group LLC purchased a new position in shares of Daré Bioscience during the fourth quarter worth about $52,000. 6.70% of the stock is currently owned by hedge funds and other institutional investors.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.